title: Intralesional meglumine antimoniate for treatment of cutaneous leishmaniasis patients with contraindication to systemic therapy from Rio de Janeiro (2000 to 2006).
abstract: We evaluated the effectiveness and safety of intralesional meglumine antimoniate (MA) in 24 not submitted to previous treatment patients with cutaneous leishmaniasis (CL) and with contraindication to systemic therapy. Each treatment consisted of one to four intralesional applications of MA at 15-day intervals. Patients' age ranged from 3 to 90 years; fourteen were females. Intralesional treatment in the absence of any relevant toxicity was successful in 20 (83.3%) patients. Three patients required additional treatment with amphotericin B and one required systemic MA. None of the patients developed mucosal lesions when followed up to 60 months. Intralesional MA is an effective and less toxic alternative treatment of patients with CL and contraindication to systemic therapy.
authors.affiliation: Evandro Chagas Clinical Research Institute, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil.
authors.forename: Erica de Camargo Ferreira E
authors.initials: Ede C
authors.lastname: Vasconcellos
authors.forename: Maria Inês Fernandes
authors.initials: MI
authors.lastname: Pimentel
authors.forename: Armando de Oliveira
authors.initials: Ade O
authors.lastname: Schubach
authors.forename: Raquel de Vasconcellos Carvalhaes
authors.initials: Rde V
authors.lastname: de Oliveira
authors.forename: Rilza Beatriz
authors.initials: RB
authors.lastname: Azeredo-Coutinho
authors.forename: Fátima da Conceição
authors.initials: Fda C
authors.lastname: Silva
authors.forename: Mariza de Matos
authors.initials: Mde M
authors.lastname: Salgueiro
authors.forename: João Soares
authors.initials: JS
authors.lastname: Moreira
authors.forename: Maria de Fátima
authors.initials: Mde F
authors.lastname: Madeira
authors.forename: Cibele
authors.initials: C
authors.lastname: Baptista
authors.forename: Cláudia Maria
authors.initials: CM
authors.lastname: Valete-Rosalino
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000981:Antiprotozoal Agents / Q000008:administration & dosage*; D001938:Brazil; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D015552:Injections, Intralesional; D007891:Leishmania / Q000254:growth & development*; D016773:Leishmaniasis, Cutaneous / Q000188:drug therapy*; D008297:Male; D008536:Meglumine / Q000008:administration & dosage*; D000077485:Meglumine Antimoniate; D008875:Middle Aged; D009942:Organometallic Compounds / Q000008:administration & dosage*; D018709:Statistics, Nonparametric; D014505:Urban Population; D055815:Young Adult
chemical_list: D000981:Antiprotozoal Agents; D009942:Organometallic Compounds; D008536:Meglumine; D000077485:Meglumine Antimoniate